Other
Cognitive Function
0
Pipeline Programs↗
7
Active Trials↗
9
Companies Involved↗
Cognitive Function is an early-stage landscape with 0 programs across 9 companies. The most active players are GSK, Neurana Pharmaceuticals, Inc., Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
79
clinical trials
Completed49 · 62%
Unknown status15 · 19%
Terminated5 · 6%
Recruiting3 · 4%
Withdrawn3 · 4%
Active, not recruiting2 · 3%
Other2 · 3%
Clinical Trials
Trial Activity
79 trials
The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients
Recruiting·—·N/A·NCT07244770·300 enrolled
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Not yet recruiting·—·Phase 2·NCT06594172·67 enrolled
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
Completed·—·N/A·NCT03062150·232 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)